|67.28 2.31 (3.56%)||11-29 10:48|
|Targets||6-month :||80.89||1-year :||94.48|
|Resists||First :||69.26||Second :||80.89|
|Supports||First :||62.56||Second :||58.43|
|MAs||MA(5) :||65.96||MA(20) :||64.06|
|MA(100) :||75.77||MA(250) :||71.48|
|MACD||MACD :||0.2||Signal :||-0.4|
|%K %D||K(14,3) :||71.2||D(3) :||68.2|
|52-week||High :||100.76||Low :||43.68|
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ EXAS ] has closed below upper band by 14.9%. Bollinger Bands are 4.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
|If tomorrow:||Open lower||Open higher|
|High:||65.52 - 65.96||65.96 - 66.32|
|Low:||62.73 - 63.16||63.16 - 63.51|
|Close:||64.34 - 65.04||65.04 - 65.62|
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; Oncotype Test, a tissue test delivering tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, or recurrent cancer; Oncotype DX AR-V7 Nucleus Detect Test, a liquid-based test for advanced stage prostate cancer; Oncomap ExTra, that provides a complete biological picture of certain refractory, rare, or aggressive cancers; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.
Tue, 28 Nov 2023
EXAS Quantitative Stock Analysis - Nasdaq
|Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
|Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
|Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
|Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
|Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
|Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Diagnostics & Research
|Shares Out||181 (M)|
|Shares Float||179 (M)|
|Held by Insiders||0.9 (%)|
|Held by Institutions||88.7 (%)|
|Shares Short||7,570 (K)|
|Shares Short P.Month||7,580 (K)|
|EPS Est Next Qtrly||0|
|EPS Est This Year||0|
|EPS Est Next Year||0|
|Book Value (p.s.)||17.26|
|Profit Margin||-11.8 %|
|Operating Margin||-10.4 %|
|Return on Assets (ttm)||-3.5 %|
|Return on Equity (ttm)||-9.1 %|
|Qtrly Rev. Growth||20.1 %|
|Gross Profit (p.s.)||8.34|
|Sales Per Share||13.32|
|Qtrly Earnings Growth||0 %|
|Operating Cash Flow||139 (M)|
|Levered Free Cash Flow||3 (M)|
|Price to Book value||3.92|
|Price to Sales||5.07|
|Price to Cash Flow||88.27|
|Dividend Pay Date||Invalid DateTime.|
|Ex-Dividend Date||Invalid DateTime.|